Furthermore, last month, Roche’s IL-6 inhibitor Actemra/RoActemra (tocilizumab) also failed to show a benefit in an Italian study involving patients with early-stage COVID-19 pneumonia.

UK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 inhibitor will succeed where class rivals from Roche and Sanofi/Regeneron have failed.

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery of COVID-19 patients ... Head of Clinical Pharmacology at Medical ...

A World Health Organization (WHO) panel on Friday strongly recommended baricitinib, a drug used for treatment of rheumatoid arthritis, for patients with severe or critical Covid-19 in combination ...